AstraZeneca to Invest $50 Billion in US, Bringing Pharmaceutical Production to Commonwealth of Virginia

AstraZeneca plans to invest $50 billion in the US by 2030, with a focus on pharmaceutical production. The investment includes a new manufacturing facility in Virginia, as well as expansions in R&D facilities in Maryland and Massachusetts, manufacturing facilities in Maryland, California, and Texas, and new sites to supply clinical trials. The investment aims to deliver AstraZeneca's ambition of reaching $80 billion in total revenue by 2030, with 50% generated in the US.

Title: AstraZeneca's $50 Billion Investment in the US by 2030

AstraZeneca has announced a significant investment of $50 billion in the United States over the next five years, with a focus on pharmaceutical production and research and development (R&D). The investment aims to bolster the company's ambition to reach $80 billion in total revenue by 2030, with 50% of this revenue expected to come from the US market.

The cornerstone of this investment is a new multi-billion dollar drug substance manufacturing facility planned for the Commonwealth of Virginia. This facility will produce drug substances for AstraZeneca's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule products. The facility is expected to leverage advanced technologies such as artificial intelligence, automation, and data analytics to optimize production.

In addition to the Virginia manufacturing site, AstraZeneca plans to expand its R&D facilities in Gaithersburg, Maryland, and construct a new research facility in Kendall Square, Cambridge, Massachusetts. The company will also increase the capability of its gene therapy production facilities in Rockville, Maryland, and Tarzana, California, as well as its plants in Mount Vernon, Indiana, and Coppell, Texas. Furthermore, AstraZeneca is establishing new locations to support clinical trials and increasing its investment in the development of novel medicines.

The investment is part of AstraZeneca's broader strategy to strengthen America's role in medicine manufacturing and R&D. The company expects the investment to create tens of thousands of new, highly skilled direct and indirect jobs across the country, supporting growth and delivering next-generation medicines for patients in the US and worldwide.

AstraZeneca's CEO, Pascal Soriot, stated that the investment reflects the company's belief in America's innovation in biopharmaceuticals and its commitment to patients. The investment also underscores the critical role the US plays in AstraZeneca's ability to deliver on its ambition to launch 20 new medicines by the end of the decade.

The announcement has been well-received by US officials. Howard Lutnick, US Secretary of Commerce, highlighted the importance of ending reliance on foreign supply of key pharmaceutical products. Governor Glenn Youngkin of the Commonwealth of Virginia praised the investment, noting that it will set the standard for technological advancements in pharmaceutical manufacturing and create hundreds of highly skilled jobs.

References:
1. [AstraZeneca Press Release](https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html)
2. [NASDAQ Article](https://www.nasdaq.com/articles/astrazeneca-invest-50-bln-us-2030-boost-medicine-production-and-research)
3. [FiercePharma Article](https://www.fiercepharma.com/manufacturing/astrazeneca-plans-50b-investment-us-including-massive-plant-virginia)